UNSPSC 51132227: Aluminum hydroxide/aspirin/magnesium hydroxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132227 Aluminum hydroxide/aspirin/magnesium hydroxide is a Commodity code, but the recent state and local opportunities tagged under it diverge significantly from its nominal scope—they solicit naloxone, safe drug deactivation systems, and multi-source generic pharmaceuticals and OTC products rather than the specific antacid and pain-relief formulation the code describes. State and local governments use this code family to procure a broad range of pharmaceutical products and medical supplies, including emergency medications, controlled-substance management systems, and generic pharmaceutical inventories distributed through established wholesaler networks. Issuing bodies span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The Seminole County procurement targets community health initiatives with quarterly deliveries of naloxone and drug deactivation systems, while the Texas HHS Commission and Minnesota Department of Administration are exploring or executing larger-scale generic pharmaceutical and OTC product supply agreements.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB60459723LAS (closed July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a two-year initial term and one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, administering the multistate cooperative purchasing alliance MMCAP, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson—with contract effectiveness July 1, 2026. MMCAP requires vendors to certify cGMP and Drug Supply Chain Security Act compliance, maintain $5,000,000 commercial general liability coverage, and accept a 3 percent administrative fee on all contract purchases. The code shows active state and local pharmaceutical procurement but limited direct alignment with its nominal antacid-formulation scope.